Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr David Sheridan.

Newcastle AuthorsTitleYearFull text
Dr David Sheridan
Professor Stuart McPherson
National study of NAFLD management identifies variation in delivery of care in the UK between 2019-20222023
Professor David Jones
Dr David Sheridan
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis2022
Dr David Sheridan
Dr Daniel Felmlee
Dr Simon Bridge
Emeritus Professor Margaret Bassendine
Infection with the hepatitis C virus causes viral genotype-specific differences in cholesterol metabolism and hepatic steatosis2022
Dr David Sheridan
Professor Quentin Anstee
Professor Stuart McPherson
Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey2017
Emeritus Professor Margaret Bassendine
Dr Soren Nielsen
Dr Simon Bridge
Dr Daniel Felmlee
Dr David Sheridan
et al.
Hepatitis C virus and atherosclerosis: A legacy after virologic cure?2017
Dr Luca Miele
Dr David Sheridan
Diverse Impacts of the rs58542926 E167K Variant in TM6SF2 on Viral and Metabolic Liver Disease Phenotypes2016
Dr David Sheridan
FibroGENE: A gene-based model for staging liver fibrosis2016
Dr David Sheridan
Fiona Fenwick
Emeritus Professor Margaret Bassendine
Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection2016
Professor Quentin Anstee
Dr David Sheridan
Staging fibrosis and excluding advanced fibrosis in patients with NAFLD: comparison of non-invasive markers in an interim analysis from a prospective multicentre study2016
Dr David Sheridan
Professor Margaret Bassendine
Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease2015
Dr David Sheridan
Dr Simon Bridge
Dr Daniel Felmlee
Emeritus Professor Margaret Bassendine
Lipidomics analysis of fasting serum identifies novel lipid biomarkers specific for HCV genotype 3 and genotype 1 chronic hepatitis C virus infection2015
Dr Simon Bridge
Dr David Sheridan
Dr Daniel Felmlee
Fiona Fenwick
Dr Clare Lanyon
et al.
PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: Evidence for genotype-specific regulation of lipoprotein metabolism2015
Dr David Sheridan
Dr Simon Bridge
Dr Daniel Felmlee
Dr R Neely
Emeritus Professor Margaret Bassendine
et al.
Depressive symptoms in chronic hepatitis C are associated with plasma apolipoprotein E deficiency2014
Dr David Sheridan
Emeritus Professor Margaret Bassendine
Hepatitis C lipoviral particle levels are associated with spontaneous clearance of acute infection2014
Dr David Sheridan
IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection2014
Dr David Sheridan
Dr Simon Bridge
Dr Daniel Felmlee
Fiona Fenwick
Dr R Neely
et al.
Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy - a pilot randomised clinical trial2014
Professor Margaret Bassendine
Dr David Sheridan
Jaime Jonsson
CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection2013
Dr David Sheridan
Dr R Neely
Professor Margaret Bassendine
Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs)2013
Professor Margaret Bassendine
Dr David Sheridan
Dr Simon Bridge
Dr Daniel Felmlee
Dr R Neely
et al.
Lipids and HCV2013
Dr David Sheridan
Dr Daniel Felmlee
Dr Simon Bridge
Fiona Fenwick
Emeritus Professor Geoffrey Toms
et al.
Metabolic Syndrome and Insulin Resistance are Associated with Maximum Hepatitis C Lipoviral Particles in Genotype 1 Infection2013
Dr David Sheridan
Dr Simon Bridge
Dr Daniel Felmlee
Fiona Fenwick
Professor Margaret Bassendine
et al.
Omega-3 Fatty Acids and/or Fluvastatin in Hepatitis C Prior Non-Responders to Combination Anti-Viral Therapy - A Pilot Randomised Clinical Trial2013
Dr David Sheridan
Dr Simon Bridge
Dr Daniel Felmlee
Emeritus Professor Geoffrey Toms
Dr R Neely
et al.
Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: Evidence for an association with interferon sensitivity2012
Professor Margaret Bassendine
Dr David Sheridan
IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study2011
Dr Simon Bridge
Dr David Sheridan
Dr Daniel Felmlee
Emeritus Professor Geoffrey Toms
Professor Margaret Bassendine
et al.
Apolipoprotein E and low-density, apolipoprotein B associated lipoviral particles in chronic Hepatitis C infection: Evidence for genotype-specific modulation of lipid pathways2011
Professor Margaret Bassendine
Dr David Sheridan
Dr Daniel Felmlee
Dr Simon Bridge
Emeritus Professor Geoffrey Toms
et al.
HCV and the hepatic lipid pathway as a potential treatment target2011
Dr Daniel Felmlee
Dr David Sheridan
Dr Simon Bridge
Emeritus Professor Geoffrey Toms
Professor Margaret Bassendine
et al.
Use of intralipid infusion to analyse apolipoprotein B (APOB) and HCV RNA kinetics in chronic infection2011
Dr David Sheridan
Professor Kim Bartlett
Dr Daniel Felmlee
Dr Simon Bridge
Emeritus Professor Geoffrey Toms
et al.
Hypocholesterolaemia in chronic hepatitis C genotype 3 infection is due to both reduced cholesterol production and increased LDL clearance2010
Dr David Sheridan
Professor Kim Bartlett
Dr Daniel Felmlee
Dr Simon Bridge
Emeritus Professor Geoffrey Toms
et al.
Hypocholesterolaemia in chronic Hepatitis C virus (HCV) infection - Reduced production or increased LDL clearance?2010
Dr Simon Bridge
Dr David Sheridan
Dr Daniel Felmlee
Dr Soren Nielsen
Dr R Neely
et al.
Insulin resistance and low-density apolipoprotein B-associated lipoviral particles in hepatitis C virus genotype 1 infection2010
Dr Simon Bridge
Dr David Sheridan
Dr Daniel Felmlee
Dr Soren Nielsen
Dr R Neely
et al.
Insulin resistance correlates with low density hepatitis C virus particles in genotype 1 infection2010
Dr Daniel Felmlee
Dr David Sheridan
Dr Simon Bridge
Dr Soren Nielsen
Emeritus Professor Geoffrey Toms
et al.
Intravascular Transfer Contributes to Postprandial Increase in Numbers of Very-Low-Density Hepatitis C Virus Particles2010
Dr Simon Bridge
Dr David Sheridan
Dr Daniel Felmlee
Emeritus Professor Geoffrey Toms
Dr R Neely
et al.
Low density Hepatitis C virus particles (lipoviral particles) associate with insulin resistance in genotype 1 infection2010
Dr Simon Bridge
Dr David Sheridan
Dr Daniel Felmlee
Emeritus Professor Geoffrey Toms
Professor Margaret Bassendine
et al.
Measurement of low-density Apolipoprotein B associated lipoviral particles in hepatitis C virus genotype 1 infection is more clinically relevant than total viral load2010
Dr Daniel Felmlee
Dr David Sheridan
Dr Simon Bridge
Emeritus Professor Geoffrey Toms
Professor Margaret Bassendine
et al.
The HCV life-cycle in the vascular compartment2010
Dr Monique Welten
Professor Margaret Bassendine
Dr David Sheridan
Dr James George
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy2009
Dr Simon Bridge
Dr David Sheridan
Dr Daniel Felmlee
Dr Soren Nielsen
Emeritus Professor Geoffrey Toms
et al.
Apolipoprotein B Associated Hepatitis C Virus (HCV): A Minority of Total Viral Load in Patients with Chronic HCV2009
Dr David Sheridan
Dr David Price
Dr Matthias Schmid
Emeritus Professor Geoffrey Toms
Dr Peter Donaldson
et al.
Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin2009
Dr Daniel Felmlee
Dr Simon Bridge
Dr David Sheridan
Dr Soren Nielsen
Emeritus Professor Geoffrey Toms
et al.
Large and Buoyant Hepatitis C Virus (HCV) Particles Surge after Patients Consume a High-Fat Meal2009
Dr David Sheridan
Dr David Price
Dr Matthias Schmid
Emeritus Professor Geoffrey Toms
Apolipoprotein B associated cholesterol level is a predictor of response to therapy in chronic hepatitis C2008